Investor FAQs

 

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,200 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

NanoString’s ticker is NSTG.

NanoString trades on the NASDAQ exchange under the ticker symbol “NSTG”.

No, NanoString does not offer a direct stock purchase program.

NanoString’s SEC filings are available by selecting the “Financial Information” section of our “Investors” page on our website or through SEC’s website (www.sec.gov).

NanoString’s fiscal year ends December 31st.

NanoString has not yet determined when it will hold its next  Annual Stockholder Meeting.  The last meeting was held on July 15, 2016. 

NanoString’s independent auditor is PricewaterhouseCoopers LLP.

NanoString uses American Stock Transfer as its transfer agent. You can contact them by mail at: 6201 15th Avenue, Brooklyn, NY 11219 or by telephone: (800) 937-5449 or (718) 921-8124.

NanoString’s outside legal counsel is Wilson Sonsini Goodrich & Rosati.

No, NanoString does not pay a dividend at this time.

The biographies of NanoString’s officers and directors are available in the “Corporate Governance” section of our website.

NanoString completed its initial public offering of 5,400,000 shares at a price of $10.00 per share on June 26, 2013.

Please see our “Events & Presentations” section of our website for a listing of upcoming earnings announcements and other key events.

You can contact NanoString’s Investor Relations via email by clicking here or by dialing (206) 378-NANO.

The Company’s headquarters is located at 530 Fairview Avenue North in Seattle, Washington.

NanoString Technologies, Inc. was incorporated in the state of Delaware on June 20, 2003.

The IPO was underwritten and managed by J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Swann LLC, and Robert W. Baird & Co. Incorporated.

If your shares are held in street name (by your broker), you must notify the securities firm holding your stock.  If you hold stock certificates in your name, address changes should be submitted in writing by U.S. Mail to our transfer agent: American Stock Transfer, 6201 15th Avenue, Brooklyn, NY 11219.  Telephone: (800) 937-5449 and (718) 921-8124.

If you hold stock certificates in your name, please contact our transfer agent regarding the replacement of lost certificates: American Stock Transfer, 6201 15th Avenue, Brooklyn, NY 11219.  Telephone: (800) 937-5449 and (718) 921-8124.

Please submit your question using the form below.

Contact Form
* Indicates required field
http://apps.shareholder.com/captcha/captcha.aspx?verifyid=1972292307&CompanyID=AMDA-1VDD38&t=.jpg